Loading...
ROCO
3118
Market cap31mUSD
Oct 08, Last price  
31.30TWD
1D
0.00%
1Q
-1.26%
Jan 2017
3.30%
IPO
-6.09%
Name

Level Biotechnology Inc

Chart & performance

D1W1MN
ROCO:3118 chart
P/E
12.75
P/S
1.38
EPS
2.46
Div yield, %
5.75%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
1.84%
Revenues
737m
+0.72%
379,552,000390,622,000462,580,000468,520,000527,452,000497,092,000470,027,000528,973,000533,305,000519,965,000513,542,000577,633,000629,029,000638,903,000672,492,000677,279,000593,013,000660,611,000731,347,000736,593,000
Net income
80m
+22.97%
39,028,00040,105,00060,311,00048,158,00072,051,00060,304,00052,949,00064,607,00076,836,00078,392,00063,262,00068,314,00038,914,00047,397,00058,042,00068,179,00058,466,00062,905,00064,811,00079,699,000
CFO
60m
-7.00%
86,555,00051,262,000134,159,00056,261,00053,198,00095,787,000101,528,00097,665,00079,090,00071,289,00026,773,000109,022,00083,227,000155,950,00065,072,00070,210,00064,097,00059,608,000
Dividend
Jun 10, 20262.2 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immunology, and molecular biology, alongside advanced biomedical instrumentation, throughout Taiwan. Beyond product distribution, Level Biotechnology offers a comprehensive suite of research and testing services. These include expert assessments in mammalian and genetic toxicology, pharmacological studies, biocompatibility testing, and the production of model animals. The firm's preclinical research capabilities serve a diverse range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries.

Key people

Chunlung Chiu
Chairman of the Board, General Manager · since 2013
Yixian Li
Finance Manager, Corporate Governance Officer · since 2022
Chia-Hsien Yeh
General Manager · since 2025
Yung-Feng Chang
Director · since 2010
Yi-Chun Chiu
Deputy General Manager-Instrument Business, Director · since 1997
Director · since 2019
Li-Feng Shao
Director · since 2019
Hsi-Ting Wang
Director · since 2010
Independent Director · since 2022
Independent Director · since 2019
Yung-Sen Liu
Independent Director · since 2019
IPO date
Sep 10, 2004
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT